Zacks Research Research Analysts Decrease Earnings Estimates for Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Equities research analysts at Zacks Research dropped their FY2025 EPS estimates for Sanofi in a report issued on Tuesday, October 15th. Zacks Research analyst K. Shah now expects that the company will earn $4.69 per share for the year, down from their prior forecast of $4.70. The consensus estimate for Sanofi’s current full-year earnings is $4.25 per share. Zacks Research also issued estimates for Sanofi’s Q1 2026 earnings at $1.33 EPS and FY2026 earnings at $5.08 EPS.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. During the same period in the prior year, the firm earned $0.95 EPS. The firm’s revenue was up 7.8% on a year-over-year basis.

SNY has been the topic of several other research reports. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday. Argus increased their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Sanofi has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Down 0.2 %

Shares of SNY stock opened at $54.44 on Thursday. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97. The firm has a market capitalization of $137.88 billion, a PE ratio of 27.36, a P/E/G ratio of 1.56 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The stock’s 50-day simple moving average is $56.00 and its 200-day simple moving average is $51.46.

Hedge Funds Weigh In On Sanofi

Several hedge funds have recently bought and sold shares of the company. Boston Partners lifted its holdings in Sanofi by 0.3% during the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock worth $635,280,000 after buying an additional 33,657 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC boosted its holdings in Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares in the last quarter. Mondrian Investment Partners LTD increased its stake in Sanofi by 43.1% in the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after purchasing an additional 1,190,141 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in Sanofi by 8.2% during the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after purchasing an additional 246,224 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.